Department of Medicine, Division of Endocrinology, The University of Arizona College of Medicine, 1501 N. Campbell Ave, PO Box 245035, Tucson, AZ, 85724-5035, USA.
Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ, USA.
Clin Epigenetics. 2021 May 1;13(1):100. doi: 10.1186/s13148-021-01086-6.
The mechanisms of weight loss and metabolic improvements following bariatric surgery in skeletal muscle are not well known; however, epigenetic modifications are likely to contribute. The aim of our study was to investigate skeletal muscle DNA methylation after weight loss induced by Roux-en-Y gastric bypass (RYGB) surgery. Muscle biopsies were obtained basally from seven insulin-resistant obese (BMI > 40 kg/m) female subjects (45.1 ± 3.6 years) pre- and 3-month post-surgery with euglycemic hyperinsulinemic clamps to assess insulin sensitivity. Four lean (BMI < 25 kg/m) females (38.5 ± 5.8 years) served as controls. We performed reduced representation bisulfite sequencing next generation methylation on DNA isolated from the vastus lateralis muscle biopsies.
Global methylation was significantly higher in the pre- (32.97 ± 0.02%) and post-surgery (33.31 ± 0.02%) compared to the lean (30.46 ± 0.02%), P < 0.05. MethylSig analysis identified 117 differentially methylated cytosines (DMCs) that were significantly altered in the post- versus pre-surgery (Benjamini-Hochberg q < 0.05). In addition, 2978 DMCs were significantly altered in the pre-surgery obese versus the lean controls (Benjamini-Hochberg q < 0.05). For the post-surgery obese versus the lean controls, 2885 DMCs were altered (Benjamini-Hochberg q < 0.05). Seven post-surgery obese DMCs were normalized to levels similar to those observed in lean controls. Of these, 5 were within intergenic regions (chr11.68,968,018, chr16.73,100,688, chr5.174,115,531, chr5.1,831,958 and chr9.98,547,011) and the remaining two DMCs chr17.45,330,989 and chr14.105,353,824 were within in the integrin beta 3 (ITGB3) promoter and KIAA0284 exon, respectively. ITGB3 methylation was significantly decreased in the post-surgery (0.5 ± 0.5%) and lean controls (0 ± 0%) versus pre-surgery (13.6 ± 2.7%, P < 0.05). This decreased methylation post-surgery was associated with an increase in ITGB3 gene expression (fold change + 1.52, P = 0.0087). In addition, we showed that ITGB3 promoter methylation in vitro significantly suppressed transcriptional activity (P < 0.05). Transcription factor binding analysis for ITGB3 chr17.45,330,989 identified three putative transcription factor binding motifs; PAX-5, p53 and AP-2alphaA.
These results demonstrate that weight loss after RYGB alters the epigenome through DNA methylation. In particular, this study highlights ITGB3 as a novel gene that may contribute to the metabolic improvements observed post-surgery. Future additional studies are warranted to address the exact mechanism of ITGB3 in skeletal muscle.
减重手术(如 Roux-en-Y 胃旁路术,RYGB)后体重减轻和代谢改善的机制尚不清楚;然而,表观遗传修饰可能起到一定作用。我们的研究旨在探究 RYGB 术后骨骼肌 DNA 甲基化的变化。从 7 名胰岛素抵抗肥胖(BMI>40 kg/m2)女性患者(45.1±3.6 岁)中获得术前和术后 3 个月的肌肉活检,使用正葡萄糖高胰岛素钳夹术评估胰岛素敏感性。4 名瘦(BMI<25 kg/m2)女性作为对照组(38.5±5.8 岁)。我们对取自股外侧肌活检的 DNA 进行简化代表性双硫代嘧啶测序下一代甲基化分析。
与瘦对照组(30.46±0.02%)相比,术前(32.97±0.02%)和术后(33.31±0.02%)的骨骼肌整体甲基化水平显著升高,P<0.05。MethylSig 分析鉴定出 117 个差异甲基化胞嘧啶(DMC),这些 DMC 在术后与术前相比发生了显著变化(Benjamini-Hochberg q<0.05)。此外,术前肥胖与瘦对照组之间有 2978 个 DMC 发生了显著变化(Benjamini-Hochberg q<0.05)。术后肥胖与瘦对照组之间有 2885 个 DMC 发生了变化(Benjamini-Hochberg q<0.05)。术后肥胖组中 7 个 DMC 恢复到与瘦对照组相似的水平。其中,5 个位于基因间区域(chr11.68,968,018、chr16.73,100,688、chr5.174,115,531、chr5.1,831,958 和 chr9.98,547,011),其余两个 DMC 位于整合素 beta 3(ITGB3)启动子和 KIAA0284 外显子内,chr17.45,330,989 和 chr14.105,353,824。术后(0.5±0.5%)和瘦对照组(0±0%)的 ITGB3 甲基化水平明显低于术前(13.6±2.7%,P<0.05)。术后这种低甲基化与 ITGB3 基因表达增加(倍数变化+1.52,P=0.0087)相关。此外,我们表明体外 ITGB3 启动子甲基化显著抑制转录活性(P<0.05)。对 chr17.45,330,989 处的 ITGB3 进行转录因子结合分析,确定了三个可能的转录因子结合基序;PAX-5、p53 和 AP-2alphaA。
这些结果表明,RYGB 术后体重减轻会通过 DNA 甲基化改变表观基因组。特别是,本研究强调了 ITGB3 作为一种新基因,可能有助于术后代谢改善。未来需要进一步研究来阐明 ITGB3 在骨骼肌中的确切作用机制。